Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …
The interaction between pulmonary fibrosis and COVID-19 and the application of related anti-fibrotic drugs
H Shen, N Zhang, Y Liu, X Yang, Y He, Q Li… - Frontiers in …, 2022 - frontiersin.org
COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs.
Critically ill patients are easily complicated by cytokine storms, acute respiratory distress …
Critically ill patients are easily complicated by cytokine storms, acute respiratory distress …
Post-COVID-19 pneumonia pulmonary fibrosis
S Tale, S Ghosh, SP Meitei, M Kolli… - … Journal of Medicine, 2020 - academic.oup.com
Discussion Clinical manifestations of Corona virus disease-2019 (COVID-19) have ranged
from asymptomatic/mild symptoms to severe illness and mortality. 1 Most of the mild and …
from asymptomatic/mild symptoms to severe illness and mortality. 1 Most of the mild and …
Pulmonary fibrosis secondary to COVID-19: a call to arms?
P Spagnolo, E Balestro, S Aliberti… - The Lancet …, 2020 - thelancet.com
As of May 6, 2020, nearly 3· 7 million people have been infected and around 260 000
people have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all …
people have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all …
Pathophysiology of pulmonary fibrosis in the context of COVID-19 and implications for treatment: A narrative review
S Tran, A Ksajikian, J Overbey, P Li, Y Li - Cells, 2022 - mdpi.com
Pulmonary fibrosis (PF) is a feared outcome of many pulmonary diseases which results in a
reduction in lung compliance and capacity. The development of PF is relatively rare, but it …
reduction in lung compliance and capacity. The development of PF is relatively rare, but it …
Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic
SR Ambardar, SL Hightower, NA Huprikar… - Journal of clinical …, 2021 - mdpi.com
Since the initial identification of the novel coronavirus SARS-CoV-2 in December 2019, the
COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As …
COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As …
Lung fibrosis: an undervalued finding in COVID-19 pathological series
With the COVID-19 pandemic having reached tremendous proportions, post-mortem series
are under the limelight to explain many of the peculiar clinical findings. Pathological …
are under the limelight to explain many of the peculiar clinical findings. Pathological …
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients
C Giacomelli, R Piccarducci, L Marchetti… - Biochemical …, 2021 - Elsevier
Pulmonary fibrosis (PF) is characterised by several grades of chronic inflammation and
collagen deposition in the interalveolar space and is a hallmark of interstitial lung diseases …
collagen deposition in the interalveolar space and is a hallmark of interstitial lung diseases …
[HTML][HTML] Post-COVID-19 pulmonary fibrosis
A Mohammadi, I Balan, S Yadav, WF Matos… - Cureus, 2022 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions
worldwide with a high mortality rate due to a lack of definitive treatment. Despite having a …
worldwide with a high mortality rate due to a lack of definitive treatment. Despite having a …
COVID-19 patients with pulmonary fibrotic tissue: clinical pharmacological rational of antifibrotic therapy
A Vitiello, C Pelliccia, F Ferrara - SN Comprehensive Clinical Medicine, 2020 - Springer
In December 2019, the first data emerged from Wuhan, China, of a serious acute respiratory
disease caused by a new coronavirus, SARS-CoV-2 (COVID-19). In a short time, the health …
disease caused by a new coronavirus, SARS-CoV-2 (COVID-19). In a short time, the health …
相关搜索
- covid 19 pulmonary fibrosis
- antifibrotic therapy pulmonary fibrosis
- antifibrotic therapy covid 19
- disease severity pulmonary fibrosis
- disease severity covid 19
- converging pathways pulmonary fibrosis
- real threat pulmonary fibrosis
- implications for treatment pulmonary fibrosis
- therapeutic interventions pulmonary fibrosis
- molecular mechanisms pulmonary fibrosis
- converging pathways covid 19
- implications for treatment covid 19